THERAPY DOSSIER · th-abe2e8dc5138

Carbon monoxide-enriched red blood cells (CO-RBCs), a biomimetic carbon monoxide delivery system

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31924689 ↗2020Reported benefit

Carbon Monoxide Rescues the Developmental Lethality of Experimental Rat Models of Rhabdomyolysis-Induced Acute Kidney Injury

RatCrushLimb / muscle crushSprague-Dawley

Model: Rat models of acute kidney injury induced by traumatic and non-traumatic rhabdomyolysis, comprising crush syndrome, rhabdomyolysis combined with massive haemorrhagic shock, and glycerol-induced rhabdomyolysis

A single CO-RBC treatment suppressed the pathogenesis of acute kidney injury and improved mortality in crush syndrome and in rhabdomyolysis with massive haemorrhagic shock model rats, and likewise reduced acute kidney injury and mortality in glycerol-induced rhabdomyolysis rats, with renoprotection…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…